Take a trial of UK to unlock this pageFind out more
© Stockopedia 26th February, 2017

AstraZeneca

AZN 4609p 8.5  0.2%
24/02/17 0.500k

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 2 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2011 2012 2013 2014 2015 2016 2017E 2018E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 16th Feb, paid: 20th Mar more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ -8.2%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2016, AstraZeneca plc revenues decreased 7% to $23B. Net income increased 24% to $3.5B. Revenues reflect Product sales decrease of 10% to $21.32B. Net income reflects Selling, General & Administrative Expens decrease of 12% to $8.17B (expense), Selling, General - Acquisition of BMS S decrease from $54M (expense) to $627M (income). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
A-
A-
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Dec '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2017
31st Dec 2018

Price Target: $62.7
(+8.41% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +3.5% ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
35 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 2 11 10 10

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Matthew Weston , Piper Jaffray Richard Purkiss , SEB Equities Richard Koch , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , Investec Bank (UK) Plc Andrew Whitney , Danske Markets Lars Hevreng , Natixis Jean-Jacques Le Fur , Mirabaud Securities Nicholas Turner , Swedbank Markets Johan Unnerus , Nordea Markets Michael Novod , Societe Generale Justin Smith , Pareto Securities AS Finlay Heppenstall , Berenberg Alistair Campbell , Oddo Securities Pierre Corby , Helvea SA Odile Rundquist , Shore Capital Stockbrokers Tara Raveendran , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Cantor Fitzgerald Europe Brian White , Baader Helvea Equity Research Odile Rundquist , Foveal Amit Roy ,

Profile Summary

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Directors: Pascal Soriot (CEO) 57, Marc Dunoyer (CFO) 63, Fiona Cicconi (EVP) , Sean Bohen (EVP) , Pam Cheng (EVP) 45, Ruud Dobber (EVP) , Paul Hudson (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Luke Miels (EVP) , Leif Johansson (NEC) 65, Tim Jackson-Smith (NED) , Marcus Wallenberg (NED) 60, Genevieve Berger (NID) 61, Bruce Burlington (NID) 67,

No. of Employees: 61,500 No. of Shareholders: n/a


Last Annual December 31st, 2016
Last Interim December 31st, 2016
Incorporated June 17, 1992
Public Since September 21, 2007
Shares in Issue 1,265,278,295
Free Float 1.26bn (99.6%)

Address - Legal Department 2 Kingdom Street, LONDON, W2 6BD, United Kingdom
Web http://www.astrazeneca.com/
Phone +44 20 73045000
Contact Thomas Larsen (IR Contact Officer)
Auditors KPMG LLP

AZN Share Price Performance AZNQuote
4609p
8.5  0.2%
Traded 5:04pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Tuesday 28th February, 2017
AstraZeneca PLC at Credit Suisse Global Healthcare Conference
Thursday 2nd March, 2017
AstraZeneca PLC at Daiwa/Bernstein Investment Conference Tokyo
Monday 13th March, 2017
AstraZeneca PLC at Exane BNP Healthcare Conference
Thursday 16th March, 2017
AstraZeneca PLC at Goldman Sachs European Corporate Conference
Tuesday 14th March, 2017
AstraZeneca PLC at Barclays Global Healthcare Conference
Thursday 27th April, 2017
Q1 2017 AstraZeneca PLC Earnings Release
Thursday 27th April, 2017
AstraZeneca PLC Annual Shareholders Meeting
Tuesday 6th June, 2017
AstraZeneca PLC Investor Science Event at ASCO 2017
Thursday 27th July, 2017
Q2 2017 AstraZeneca PLC Earnings Release

Recent ↓
Thursday 16th February, 2017
Dividend For AZN
Wednesday 15th February, 2017
Dividend For AZN
Monday 6th February, 2017
AstraZeneca PLC Investor Roadshow - Europe and North America
Thursday 2nd February, 2017
Full Year 2016 AstraZeneca PLC Earnings Call
Thursday 2nd February, 2017
Full Year 2016 AstraZeneca PLC Earnings Media Conference
Thursday 2nd February, 2017
Full Year 2016 AstraZeneca PLC Earnings Release
Tuesday 10th January, 2017
AstraZeneca PLC at SEB Nordic Seminar
Thursday 15th December, 2016
AstraZeneca PLC Second Year-End Late-Stage Pipeline Investor Science Presentation
Monday 5th December, 2016
AstraZeneca PLC at Berenberg European Conference
Thursday 1st December, 2016
AstraZeneca PLC at Deutsche Bank dbAccess Pharmaceutical and Healthcare Corporate Day
Thursday 24th November, 2016
AstraZeneca PLC Investor Roadshow - London
Thursday 17th November, 2016
AstraZeneca PLC Investor Roadshow - US West Coast
Monday 14th November, 2016
AstraZeneca PLC Investor Roadshow- US East Coast
Thursday 17th November, 2016
AstraZeneca PLC Investor Roadshow- Basel
Wednesday 16th November, 2016
AstraZeneca PLC Investor Roadshow- Geneva
Tuesday 15th November, 2016
AstraZeneca PLC at Stifel Healthcare Conference
Monday 14th November, 2016
AstraZeneca PLC at Bryan Garnier European Healthcare Conference
Thursday 10th November, 2016
Q3 2016 AstraZeneca PLC Earnings Call
Thursday 10th November, 2016
Q3 2016 AstraZeneca PLC Earnings Release
Tuesday 4th October, 2016
Aralez Pharmaceuticals Inc to Acquire From AstraZeneca U.S. Rights to Beta Blocker Toprol-XL Corporate Call


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2017.


Should you buy AZN

Access AZN Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder